Millions of men and women of all ethnicities and skin types have realized the many benefits of Botox Cosmetic (botulinum toxin type A). you can, too!
Botox Cosmetic can eliminate frown lines, crow’s-feet and forehead lines quickly and without any downtime. It is the nation’s most popular nonsurgical cosmetic procedure. Botox injections are approved by the FDA to temporarily improve the appearance of moderate to severe facial wrinkles.
BOTOX®
BOTOX CAN TRANSFORM YOUR LOOK BY ADDRESSING
- Vertical frown lines between the eyebrows
- Horizontal lines on the nose
- Horizontal forehead wrinkles
- Laugh lines around eyes that extend down the cheek
- Vertical lines on the upper lip (smoker’s lip)
- Downturned or droopy lips at the corners of the mouth
NO MORE MAD, SAD, TIRED; TEN MINUTES IS ALL IT TAKES!
Dr. Rowland will perform your Botox Cosmetic treatment in approximately 10 minutes. It involves several virtually painless micro-injections into muscles that are causing wrinkles and furrows on the skin. you can expect to see a noticeable improvement within three to five days. Results may vary, but the dramatic improvement from Botox treatment can last up to four to six months.
BOTOX® is the only treatment of its type approved by the Food and Drug Administration (FDA).
DYSPORT®
Dysport, which is similar to Botox, was recently approved by the U.S. Food and Drug Administration; however, this product has been used in other countries for nearly 20 years. Dysport has been proven to temporarily reduce the appearance of wrinkles, frowns and lines. It may have a quicker onset than Botox – some patients have experienced results within hours of the injection – and is demonstrated to last a few weeks longer, too! Like Botox, it is injected to relax the muscles that cause wrinkles and furrows on the skin. Dr. Rowland will perform your Dysport treatment – to improve patient comfort, patients typically prefer to have a topical numbing cream applied before the injection. Before obtaining its FDA approval, Dysport was evaluated in more than 80 clinical study sites with approximately 2,900 patients.